Sponsor Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia.

Your donation will directly support this research project led by Dr. Madelyn Burkart at Lurie Children's Hospital.

Support This Research

Support this research directly through verified donation platforms:

Donate via Lurie Donate via LLS

Direct Support: All donations are processed securely through verified donation portals. When donating through the institution, specify that your gift supports leukemia research. LLS funds support leukemia research programs nationwide. 100% of your contribution advances leukemia research.

About This Project

There have been major paradigm shifts in the treatment of Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL) in the last decade with the introduction of new immunotherapies and targeted agents, adoption of pediatric-type chemotherapy protocols in younger adults as well as chemotherapy light approaches in older adults and the incorporation of measurable residual disease (MRD) testing to inform clinical decision making. With this, treatment outcomes in adult Ph- ALL have improved across all age groups. However, a subset of patients will still develop relapsed disease, which can be challenging to treat and associated with poor outcomes. Here we review the treatment of Ph- ALL in both younger and older adults, including the latest advancements and future directions.

Your Impact

By sponsoring this research project, you're directly contributing to advancing leukemia treatment and finding cures. Every dollar helps researchers conduct critical studies, purchase equipment, and support clinical trials that can save lives.

Back to Project Details